FDA has now rejected Replimune’s melanoma immunotherapy RP1 on two separate occasions The drug was under consideration for use with Bristol Myers Squibb’s (BMY) Opdivo therapy Regulators maintained ...

Jeff Shell is officially departing his role as president of Paramount Skydance. His exit follows a public dispute and messy legal battle with R.J. Cipriani, a professional gambler who asserts that ...

Mr. Shell, the former chief executive of NBCUniversal, is leaving after becoming entangled in a legal battle with a professional gambler, R.J. Cipriani. By Benjamin Mullin and Lauren Hirsch Jeff Shell ...

Shell signs agreements with Venezuelan government for oil and gas projects Agreements include exploration, local content, and workforce development Venezuela's oil reform aims to boost foreign ...

Competition in the world of business is a good thing for the consumer, right? It keeps prices down and forces innovation. Well, the motor oil space isn't as competitive as you might have thought. For ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Learning Python can feel like a big task, but with the freeCodeCamp Python curriculum, it gets a lot easier. I remember when I first tried to learn Python, I bounced between tutorials, books, and ...

Shell posted second-quarter profit of $4.26 billion, beating analyst expectations, and said it would buy back $3.5 billion of shares over the coming three months. The results come shortly after the ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...